The XTEND programme is funded by Sobi and Sanofi

Publication

BIC •
13 September, 2025 •
•

Joint Replacement/Revision Surgery Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Flora Peyvandi, Annette von Drygalski, Luigi Pier Solimeno, Liane Khoo, Sandrine Meunier, Elena Santagostino, Sriya Gunawardena, Meredith Foster, Linda Bystrická, Jennifer Dumont, Robert Klamroth

Available materials

Poster

Publication

BIC •
13 September, 2025 •
•

Bleed Treatment Outcomes from the XTEND-ed Study in Patients Aged 50 Years and Older

Johannes Oldenburg, Barbara A. Konkle, Toshko Lissitchkov, Pratima Chowdary, Liane Khoo, Katsuyuki Futatake, Elena Santagostino, Helena Palmborg, Linda Bystrická, Jennifer Dumont, Meredith Foster, Sriya Gunawardena, Annette von Drygalski

Available materials

Poster

Publication

BIC •
12 September, 2025 •
•

Real-World Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B by Age Groups: Final B-MORE Study Data

Heidi Glosli, Anna Olsson, Cristina Santoro, Ester Zapotocka, Martin Scott, Eva Bednar, Sabine Lauer, Stefan Lethagen

Available materials

Poster

Perioperative Management with Efanesoctocog Alfa in Patients with Haemophilia A in the XTEND Clinical Trial Programme: A European Subanalysis

Joint Replacement/Revision Surgery Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Bleed Treatment Outcomes from the XTEND-ed Study in Patients Aged 50 Years and Older

Real-World Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B by Age Groups: Final B-MORE Study Data

Extravascular distribution of factor IX: evidence and relevance for hemophilia B replacement therapy

Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Final Data from the B-MORE Study

Association between FIX levels & bleeding rates in hemophilia B patients receiving rFIXFc or N9-GP